While strong estimate revisions for kodiak sciences inc. Kodiak sciences to present at upcoming conferences.
The upgrade of kodiak sciences inc.
Kodiak sciences stock zacks. The company reported ($1.30) eps for the quarter, missing the consensus estimate of ($1.16) by ($0.14). You can see the complete list of today’s zacks #1 rank (strong buy) stocks here. 11 brokers have issued 12 month price objectives for kodiak sciences' stock.
Zacks' proprietary data indicates that kodiak sciences inc. Kodiak sciences (kod) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well. Kodiak sciences announces closing of $317.4 million public offering of common stock and full exercise of underwriters' option to purchase additional shares.
Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country. (kod) appears an attractive pick, as it has been recently upgraded to a zacks rank #2 (buy). The sole determinant of the zacks rating is a company's changing earnings picture.
Kodiak sciences announces pricing of $276.0 million public offering of. Their forecasts range from $86.00 to $170.00. Is currently rated as a zacks rank 3 and we are expecting an inline return from the kod shares relative to.
You can see the complete list of today’s zacks #1 rank (strong buy) stocks here. So, if you are looking for a decent pick in a strong industry, consider kodiak sciences. On average, they anticipate kodiak sciences' stock price to reach $132.82 in the next twelve months.
So, if you are looking for a decent pick in a strong industry, consider kodiak sciences. Kodiak sciences (kod) q2 earnings lag, eye candidate in focus. It is engaged in developing innovative therapeutics to treat the high prevalence of ophthalmic diseases.
Our research shows that stocks with zacks rank #1 (strong buy) and 2 (buy) significantly outperform the s&p 500. Kodiak sciences (nasdaq:kod) last posted its quarterly earnings data on tuesday, november 9th.
0 komentar:
Posting Komentar